1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. INTELLIA THERAPEUTICS INC

Intellia Therapeutics Inc XNAS: NTLA

Intellia Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Weak Stock
Download real time

9.31 0.31 (3.44%)

67.02% Fall from 52W High

2.5M XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Intellia Therapeutics Inc Key Metrics

Default

Market Capitalization

Below industry Median
963.7

PE TTM

Negative PE TTM
-1.9

PEG TTM

High in industry
0.2

Price to Book

Below industry Median
1.1

Institutional holding current Qtr %

High in industry
98.2

Revenue Growth Qtr YoY %

High in industry
771.6

Operating Revenue growth TTM %

Below industry Median
59.6

Net Profit Qtr Growth YoY %

Below industry Median
2.5

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-7.9

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-1,059.9

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-923.1

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-30.3

ROE Annual %

Negative ROE Annual %
-54

RoA Annual %

Negative RoA Annual %
-41.7
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
16.7 / 100
Valuation Score
Expensive Valuation
14.8 / 100
Momentum Score
Technically Bearish
19.0 / 100
Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
44
1Yr Price target upside is 372%
26 analysts

10

S

15

W

0

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Intellia Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '260100200300Actual RevenueAvg. Estimate
Hit

Intellia Therapeutics Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-5.2
Avg. Estimate
-4.7
Low Estimate
-5.7
High Estimate
-3.2
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 10.3% in FY25

Consensus Recommendation

29 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Sell7Hold4Buy17Strong Buy

The consensus recommendation from 29 analysts for Intellia Therapeutics Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Intellia Therapeutics Inc Stock Analysis

Intellia Therapeutics Inc stock analysis with key metrics, changes, and trends.

Intellia Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$57.88 M59.55%positive

Annual Revenue rose 59.55%, in the last year to $57.88 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit$519.02 M7.86%negative

Annual Net Profit fell 7.86% in the last year to $519.02 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio-1.86-negative

Price to Earning Ratio is -1.86, which is negative.

Stock Price$9.31-65.4%negative

Stock Price fell 65.4% and underperformed its sector by 75.3% in the past year.

Quarterly Revenue$12.87 M771.57%positive

Quarterly Revenue rose 771.57% YoY to $12.87 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$128.9 M2.47%positive

Quarterly Net profit rose 2.47% YoY to $128.9 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Debt to Equity Ratio0.24-positive

Debt to Equity Ratio of 0.24 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-54.00 %-54%negative

Return on Equity(ROE) for the last financial year was -54%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding70.32 %-0.42%negative

Mutual Fund Holding decreased by 0.42% in the last quarter to 70.32.

Promoter Share Holding3.81 %0.66%positive

Promoter Share Holding increased by 0.66% in the most recent quarter to 3.81%.

Institutional Holding98.16 %0%neutral

Institutional Holding remained the same in the last quarter at 98.16%.

VIEW LESS


Loading data..

Intellia Therapeutics Inc - Company Profile

What does Intellia Therapeutics Inc do?

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics Inc Management structure

All Gross Remunerations are in USD
Dr. Laura Sepp-Lorenzino, PhD
Executive Vice President and Chief Scientific Officer
-
2025
Gross Remuneration
Year
Ms. Birgit Schultes
Executive Vice President and Chief Scientific Officer
-
2025
Gross Remuneration
Year

Intellia Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Mr. Brian Goff
Independent Director
-
2024
Gross Remuneration
Year
Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D.
Independent Director
-
2024
Gross Remuneration
Year
Dr. John M. Leonard, M.D.
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Dr. Frank Verwiel, M.B.A.,M.D.
Chairman of the Board
-
2024
Gross Remuneration
Year
Mr. William J. Chase
Independent Director
-
2024
Gross Remuneration
Year
Dr. Jesse Goodman, M.D.,M.P.H.
Independent Director
-
2024
Gross Remuneration
Year

Intellia Therapeutics Inc FAQ

How is Intellia Therapeutics Inc today?
Intellia Therapeutics Inc today is trading in the green, and is up by 3.44% at 9.31.
Intellia Therapeutics Inc is currently trading up 3.44% on an intraday basis. In the past week the stock rose 1.86%. stock has been down -23.06% in the past quarter and fell -65.40% in the past year. You can view this in the overview section.